AU2013357367B2 - Modified coiled coil type proteins having improved properties - Google Patents

Modified coiled coil type proteins having improved properties Download PDF

Info

Publication number
AU2013357367B2
AU2013357367B2 AU2013357367A AU2013357367A AU2013357367B2 AU 2013357367 B2 AU2013357367 B2 AU 2013357367B2 AU 2013357367 A AU2013357367 A AU 2013357367A AU 2013357367 A AU2013357367 A AU 2013357367A AU 2013357367 B2 AU2013357367 B2 AU 2013357367B2
Authority
AU
Australia
Prior art keywords
protein
seq
modified
imx313
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013357367A
Other languages
English (en)
Other versions
AU2013357367A1 (en
Inventor
Judith DEL CAMPO ASCARATEIL
Fergal Hill
Imene TURKI HANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osivax Sas
Original Assignee
Osivax Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osivax Sas filed Critical Osivax Sas
Publication of AU2013357367A1 publication Critical patent/AU2013357367A1/en
Assigned to OSIVAX SAS reassignment OSIVAX SAS Request for Assignment Assignors: IMAXIO
Application granted granted Critical
Publication of AU2013357367B2 publication Critical patent/AU2013357367B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Analytical Chemistry (AREA)
AU2013357367A 2012-12-11 2013-12-11 Modified coiled coil type proteins having improved properties Active AU2013357367B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12306560 2012-12-11
EP12306560.9 2012-12-11
US201361802836P 2013-03-18 2013-03-18
US61/802,836 2013-03-18
PCT/EP2013/076289 WO2014090905A1 (en) 2012-12-11 2013-12-11 Modified coiled coil type proteins having improved properties

Publications (2)

Publication Number Publication Date
AU2013357367A1 AU2013357367A1 (en) 2015-06-11
AU2013357367B2 true AU2013357367B2 (en) 2019-10-24

Family

ID=47458800

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013357367A Active AU2013357367B2 (en) 2012-12-11 2013-12-11 Modified coiled coil type proteins having improved properties

Country Status (12)

Country Link
US (1) US9388225B2 (enExample)
EP (1) EP2931896B1 (enExample)
JP (1) JP6518193B2 (enExample)
KR (1) KR102237130B1 (enExample)
CN (1) CN104981541B (enExample)
AU (1) AU2013357367B2 (enExample)
BR (1) BR112015013387B8 (enExample)
CA (1) CA2893120C (enExample)
MX (1) MX363443B (enExample)
PL (1) PL2931896T3 (enExample)
RU (1) RU2677799C2 (enExample)
WO (1) WO2014090905A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520534A (ja) * 2013-03-18 2016-07-14 イマクシオＩｍａｘｉｏ インフルエンザ核タンパク質ワクチン
US10111948B2 (en) 2014-04-25 2018-10-30 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
RU2732013C1 (ru) * 2019-12-11 2020-09-10 Федеральное бюджетное учреждение науки "Государственный научный центр прикладной микробиологии и биотехнологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ПМБ) Способ сенсибилизации планшета для иммуноферментного анализа нерастворимыми белковыми антигенами
KR102613348B1 (ko) * 2020-01-07 2023-12-13 에이치케이이노엔 주식회사 알부민 및 코일드코일 형성 도메인이 연결된 융합단백질, 및 이를 이용한 이중 표적 결합체
CN115322247B (zh) * 2021-05-11 2025-07-15 中国人民解放军军事科学院军事医学研究院 一种新型冠状病毒受体结合区电荷突变体抗原及应用
WO2023025864A1 (en) 2021-08-24 2023-03-02 Osivax Immunogenic compositions and their use
JP2024545462A (ja) 2021-12-22 2024-12-06 オシバックス ワクチン組成物及びそれらの使用
CA3253732A1 (en) 2022-03-22 2023-09-28 Osivax mRNA VACCINE COMPOSITIONS AND THEIR USE
NL2031833B1 (en) 2022-05-11 2023-11-17 Univ Leiden Immunotherapeutic compositions and adjuvants
CN115779079B (zh) * 2022-10-01 2026-05-05 中国人民解放军军事科学院军事医学研究院 一种可增强与佐剂协同免疫效力的电荷调控型抗原蛋白

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012036A1 (en) * 1997-09-04 1999-03-11 Stanford University Reversible immobilization of arginine-tagged moieties on a silicate surface
JP4713809B2 (ja) * 2000-04-07 2011-06-29 ユニバーシティ オブ リードズ イノベイションズ リミテッド Ｂ型肝炎コア抗原融合タンパク質
US7270921B2 (en) * 2002-02-08 2007-09-18 Kabushiki Kaisha Toshiba Pattern writing and forming method
WO2004070012A2 (en) * 2003-02-03 2004-08-19 Palo Alto Institute Of Molecular Medicine Cell-killing molecules and methods of use thereof
US7709009B2 (en) * 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
WO2005077976A2 (en) 2004-02-13 2005-08-25 Avidis Sa Coiled-coil domains from c4b-binding protein
WO2007055288A1 (ja) * 2005-11-10 2007-05-18 National University Of Corporation Hiroshima University 酸化ケイ素含有物質に結合するタンパク質を介したタンパク質の固定化方法および固定化剤
EP1795540A1 (en) 2005-11-30 2007-06-13 Imaxio Multimeric complexes of antigens and an adjuvant
PT1996238T (pt) 2006-02-28 2016-07-11 Vaxart Inc Vetores adenovíricos quiméricos e arncd como agonista de tlr3
GB0706912D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
EP2060586A1 (en) * 2007-11-14 2009-05-20 PharmaSurgics in Sweden AB New synthetic arginine substituted peptides and their use
GB0918154D0 (en) 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
JP2016520534A (ja) * 2013-03-18 2016-07-14 イマクシオＩｍａｘｉｏ インフルエンザ核タンパク質ワクチン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"RecName: Full=Serine/Arginine-related protein 53; Short=SRrp53; AltName: Full=Arginine/serine-rich coiled-coil protein 1;", UniProt, (2001-12-01), Database accession no. Q96IZ7, URL: EBI *

Also Published As

Publication number Publication date
CA2893120C (en) 2022-03-15
JP6518193B2 (ja) 2019-05-22
RU2677799C2 (ru) 2019-01-21
WO2014090905A1 (en) 2014-06-19
AU2013357367A1 (en) 2015-06-11
EP2931896A1 (en) 2015-10-21
KR20150094697A (ko) 2015-08-19
BR112015013387B8 (pt) 2023-01-10
CN104981541A (zh) 2015-10-14
BR112015013387B1 (pt) 2022-12-20
WO2014090905A8 (en) 2014-08-21
RU2015126105A (ru) 2017-01-18
CA2893120A1 (en) 2014-06-19
US9388225B2 (en) 2016-07-12
US20150093406A1 (en) 2015-04-02
CN104981541B (zh) 2022-06-28
PL2931896T3 (pl) 2019-07-31
KR102237130B1 (ko) 2021-04-08
EP2931896B1 (en) 2019-01-16
JP2016501266A (ja) 2016-01-18
BR112015013387A2 (pt) 2017-11-14
MX2015007421A (es) 2015-12-07
MX363443B (es) 2019-03-21

Similar Documents

Publication Publication Date Title
US9388225B2 (en) Modified coiled coil type proteins having improved properties
CN114127101A (zh) 用于治疗或预防呼吸道感染的亚单位疫苗
CA2901888C (en) Influenza nucleoprotein vaccines
KR20110088526A (ko) 구제역 백신 조성물 및 이의 제조 방법
KR20230107621A (ko) 메타뉴모바이러스에 대한 단백질-기반 나노입자 백신
CN104755619B (zh) 用于预防猪水肿病的疫苗
WO2015004627A1 (en) Mutated and bacteriophage t4 nanoparticle arrayed f1-v immunogens from yersina pestis as next generation plague vaccines
CN114699521A (zh) 基于金属硫蛋白家族的免疫佐剂及其应用
JP7818245B2 (ja) 融合タンパク質及びその応用
DK2931896T3 (en) MODIFIED COILED COIL TYPE WITH IMPROVED PROPERTIES
WO2011084967A2 (en) Methods and compositions for providing protective immunity in the elderly
CN119836300A (zh) 狂犬病毒g蛋白及其用途
Kamzina et al. Virus-like particles presenting conformational epitopes as a promising vaccine platform
CN102816216A (zh) 一种可诱使颗粒化的多肽及其用途

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: OSIVAX SAS

Free format text: FORMER APPLICANT(S): IMAXIO

FGA Letters patent sealed or granted (standard patent)